BCL11A binding site in γ-globin (HBG1 and HBG2) gene promoter (None universally accepted; sometimes referred to as “BCL11A motif in γ-globin promoter”)

The BCL11A binding site in the HBG1/2 promoter is a cis-regulatory DNA motif (TGACCA) present in the promoters of the human γ-globin genes. BCL11A, a transcriptional repressor, binds this motif in adult erythroid cells to silence γ-globin and thus suppress fetal hemoglobin (HbF) expression. Natural mutations or deletions at this site (e.g., HPFH mutations) disrupt BCL11A binding, leading to increased HbF—a therapeutic goal for sickle cell disease and β-thalassemia. Modern therapeutic strategies employ genome editing (especially CRISPR-Cas9) to selectively disrupt this motif, thereby derepressing HBG1/HBG2 and reactivating fetal hemoglobin, with ongoing research focused on optimizing efficiency and minimizing safety risks[1][2][3][4][5][6][7]. This target is not a protein, enzyme, or receptor, but a critical DNA element serving as a binding site for a transcription factor that is central to gene regulation and therapeutic intervention in hemoglobinopathies.

Other names

BCL11A consensus motif in HBG1/HBG2 promoterγ-globin suppressor siteTGACCA motifHPFH site

Gene editing to disrupt the BCL11A binding site, preventing BCL11A-mediated repression and reactivating γ-globin expression, thereby increasing fetal hemoglobin (HbF) levels